Research programme: neuroprotective agents - AdvanCell/DiverDrugs
Alternative Names: DD 01012; DD 612Latest Information Update: 29 Aug 2006
Price :
$50 *
At a glance
- Originator AdvanCell; DiverDrugs
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS trauma
Most Recent Events
- 29 Aug 2006 Discontinued - Preclinical for CNS trauma in Spain (unspecified route)
- 22 Feb 2002 Preclinical development for CNS trauma in Spain (Unknown route)